Page 21 - Pharma Stocks

Chronic portfolio may help Cipla sustain growth outperformance in near term

Margin gains in the September quarter too are expected to continue

Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%

Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE

'Banking sector a good long-term bet despite expensive valuation'

The market expects a strong bounce in earnings growth in FY22 with a growth of more than 30 per cent on a YoY basis.

IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers

On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Tata Motors to Bharat Forge: Stock winners and losers in India from US Vote

Here are some key things to watch in India with respect to the upcoming US vote

Divestment of US subsidiary to leave Aurobindo Pharma cash positive

Divestment of the US subsidiary is at good valuations and will help attain net cash positive status

Edelweiss's healthcare fund offers benefit of international diversification

Allocation to a thematic offering like the newly-launched healthcare index fund should, however, be limited

GSK Pharma's growth challenges to remain in near term as Covid dents sales

Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches

Kopran hits 52-week high after Crisil upgrades rating outlook to 'Positive'

The rating agency reaffirmed its 'CRISIL BBB' rating on long term bank facilities, while short term ratings has been reaffirmed at 'CRISIL A3+'

Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high

In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma index

Solara Active Pharma surges 19% on heavy volumes, hits record high

Global brokerage Macquarie Capital Securities, on October 6, initiated coverage on the stock with an 'Outperform' rating and a target price of Rs 2,064 in bull-case scenario

IT stocks are a good bet even at the current levels: Naveen Kulkarni

IT stocks were expected to re-rate and that is happening now.

BSE Healthcare index hits record high on the back of positive news flow

The S&P BSE Healthcare index, the top gainer among sectoral indices, rose 3.5 per cent to close at 20,405 points, as compared to 0.34 per cent decline in the Sensex

Alembic gains 31% so far in September on stake purchase by promoter

As of June 30, 2020, the total promoter holding in Alembic stood at 69.57 per cent, up 195 basis points (bps) from 67.62 per cent at the end of March quarter.

Vaccine majors see sharp rally with some players rising more than 4,000%

The Indian pharmaceutical sector has also been going through a surge

New launches in key categories to trigger AstraZeneca Pharma's growth

Higher share of patented products, scope for margin improvement and chronic portfolio are key positives

Demand recovery, resumption of ops to offset weak Q1 for Jubilant Life

Growth pickup and lower debt could improve its valuations

AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%

The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.

AstraZeneca Pharma India hits fresh record high, up 15% in 8 trading days

AstraZeneca Plc, the company's parent firm, is expected to release initial data on whether a vaccine can stop people from getting the virus on September 15